NRC FORM 374	NRC	FO	RM	374
--------------	-----	----	----	-----

U.S. NUCLEAR REGULATORY COMMISSION

PAGE	1	_OF	4	PAGES
An	nendm	ent N	No. 55	,

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 39, 40, and 70, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

	nended, and is subject to all applicable rules, regulations, and order to any conditions specified below.	ers of the Nuclear Regulatory Commission how of hereafter in effect
	Licensee	In accordance with letter dated June 23, 2011,
1.	Centerpoint Medical Center of Independence, LLC d/b/a Centerpoint Medical Center	3. License number 24-18655-01 is amended in its entirety to read as follows:
2.	19600 East 39th Street	4. Expiration date January 31, 2021
	Independence, MO 64057	5. Docket No. 030-13994 Reference No.
6.	Byproduct, source, and/or special nuclear 7. Chemical a material	nd/or physical form 8. Maximum amount that licensee may possess at any one time under this license
	A. Any byproduct material A. Any permitted by 10 CFR 35.100	A. As needed
	B. Any byproduct material B. Any permitted by 10 CFR 35.200	B. As needed
	C. Any byproduct material C. Any permitted by 10 CFR 35.300	C. As needed (not to exceed one curie of iodine-131)

9. Authorized use:

- A. Any uptake, dilution and excretion study permitted by 10 CFR 35.100.
- B. Any imaging and localization study permitted by 10 CFR 35.200.
- C. Any diagnostic study or therapy procedure permitted by 10 CFR 35.300.

CONDITIONS

- Licensed material shall be used at the licensee's facilities located at 19600 East 39th Street, Independence, Missouri, and at the licensee's facilities located at 19550 East 39th Street, Independence, Missouri.
- 11. The Radiation Safety Officer for this license is Robert F. Thompson, M.D.

NRC FORM 374A	U.S. NUCLEAR REGULATORY COMMISSION		PAGE	2	of	4	PAGES
-	License Number 24-18655-01						
	MATERIALS LICENSE SUPPLEMENTARY SHEET	Docket or Reference Number 030-13994	r				
	Amendment No. 55					·	

- 12. Licensed material is only authorized for use by, or under the supervision of:
 - A. Individuals permitted to work as an authorized user, in accordance with 10 CFR 35.13 and 35.14.
 - B. The following individuals are authorized users for medical use as indicated:

Authorized Users	Material and Use
David E. Hazuka, M.D.	10 CFR 35.100, 35.200, and 35.300 (for iodine-131, limited to the oral administration of sodium iodide iodine-131).
George William Pogson, M.D.	10 CFR 35.200.
Robert F. Thompson, M.D.	10 CFR 35.100, 35.200, and 35.300 (limited to the oral administration of sodium iodide iodine-131).
Richard L. Cronemeyer, M.D.	10 CFR 35.100, 35.200, and 35.300 (for iodine-131, limited to the oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries).
Paul Ren Chu, M.D.	10 CFR 35.200.
 Stephen A. Bloom, M.D.	10 CFR 35.200.
James P. McGraw, M.D.	10 CFR 35.200.
Thomas L. Rosamond, M.D.	10 CFR 35.200.
Alan Schneider, M.D.	10 CFR 35.200.
Bob Green, M.D.	10 CFR 35.200.
Jeffrey W. Bissing, D.O.	10 CFR 35.200.
Christopher McKinney, M.D.	10 CFR 35.100, 35.200, and 35.300 (for iodine-131, limited to the oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries).
Robert G. Schwegler, M.D.	10 CFR 35.100, 35.200, and 35.300.
John E. Scott, M.D.	10 CFR 35.100, 35.200, and 35.300.
William M. Chase, M.D.	10 CFR 35.100, 35.200, and 35.300.
Craig M. Bruner, M.D.	10 CFR 35.100, 35.200, and 35.300.
Douglas W. Nemmers, M.D.	10 CFR 35.100, 35.200, and 35.300.
Michael B. Parsa, M.D.	10 CFR 35.100, 35.200, and 35.300.
Jeffrey R. Conaway, M.D.	10 CFR 35.100, 35.200, and 35.300.

U.S. NUCLEAR REGULATORY COMMISSIO	N	PAGE	3	of	4	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 24-18655-01					
	Docket or Reference Number 030-13994	er				
	Amendment No. 55					
	ERIALS LICENSE	License Number 24-18655-01 ERIALS LICENSE Docket or Reference Number 030-13994	License Number 24-18655-01 ERIALS LICENSE Docket or Reference Number 030-13994	License Number 24-18655-01 ERIALS LICENSE Docket or Reference Number 030-13994	License Number 24-18655-01 ERIALS LICENSE Docket or Reference Number 030-13994	License Number 24-18655-01 ERIALS LICENSE Docket or Reference Number 030-13994

Authorized Users	Material and Use
John F. Eurich, M.D.	10 CFR 35.100, 35.200, and 35.300.
William Brooks, M.D.	10 CFR 35.100, 35.200, and 35.300.
Kelly Hart, M.D.	10 CFR 35.100, 35.200, and 35.300.
Rick Moritz, M.D.	10 CFR 35.100, 35.200, and 35.300.
Thomas Zinn, M.D.	10 CFR 35.100, 35.200, and 35.300.
Sarah L. Sherard, M.D.	10 CFR 35.100, 35.200, and 35.300.
Donald J. Stallard, M.D.	10 CFR 35.100, 35.200, and 35.300.
Bradley Mclinay, M.D	10 CFR 35.100, 35.200, and 35.300.
Vandana Halder, M.D.	10 CFR 35.100, 35.200, and 35.300.
Leo J. Splitter, M.D.	10 CFR 35.100, 35.200, and 35.300.
Craig B. McClure, M.D.	10 CFR 35.100 and 35.200.
Robert A. Wood, Jr., M.D.	10 CFR 35.100, 35.200, and 35.300.
Joseph Philip Koury, M.D.	10 CFR 35.100 and 35.200.
Jason Eric Himmel, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to sodium iodide iodine-131 in quantities less than or equal to 33 millicuries).
Michael J. Brigg, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the use of sodium iodide iodine-131).
Nathaniel R. Jewell, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the use of sodium iodide iodine-131).
Susan Chow, M.D.	10 CFR 35.100, 35.200, and 35.300.
Michael B. Robertson, M.D.	10 CFR 35.100, 35.200 and 35.300 (limited to the use of sodium iodide iodine-131).

13. In addition to the possession limits in Item 8, the licensee shall further restrict the possession of licensed material to quantities below the minimum limit specified in 10 CFR 30.35(d) for establishing decommissioning financial assurance.

10 CFR 35.100, 35.200 and 35.300 (limited to the oral administration of sodium iodide iodine-131 in quantities less than or equal to 33 millicuries)

14. The licensee is authorized to transport licensed material in accordance with the provisions of 10 CFR Part 71, "Packaging and Transportation of Radioactive Material."

Aaron M. Lewis, M.D.

U.S. NUCLEAR REGULATORY COMMISSION		PAGE	4	of	4	PAGES
MATERIALS LICENSE SUPPLEMENTARY SHEET	License Number 24-18655-01					
	Docket or Reference Number 030-13994	r				
	Amendment No. 55					
	MATERIALS LICENSE	License Number 24-18655-01 MATERIALS LICENSE Docket or Reference Number 030-13994	License Number 24-18655-01 MATERIALS LICENSE Docket or Reference Number 030-13994	License Number 24-18655-01 MATERIALS LICENSE Docket or Reference Number 030-13994	License Number 24-18655-01 MATERIALS LICENSE Docket or Reference Number 030-13994	License Number 24-18655-01 MATERIALS LICENSE Docket or Reference Number 030-13994

- 15. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies only to those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit the licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations.
 - A. Application dated July 28, 2010 (including attachments); and
 - B. Letter dated February 18, 2011.

FOR THE U.S. NUCLEAR REGULATORY COMMISSION

Date ____SEP 2 9 2011

Cassandra F. Frazier

Materials Licensing Branch

Region III